Matches in Nanopublications for { <http://rdf.disgenet.org/nanopublications.trig#NP294057.RA8cww4AUErWn9Xu45Oy8HAeyKn1YLd1pIdZMIr1GfY_s130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP294057.RA8cww4AUErWn9Xu45Oy8HAeyKn1YLd1pIdZMIr1GfY_s130_assertion type Assertion NP294057.RA8cww4AUErWn9Xu45Oy8HAeyKn1YLd1pIdZMIr1GfY_s130_head.
- NP294057.RA8cww4AUErWn9Xu45Oy8HAeyKn1YLd1pIdZMIr1GfY_s130_assertion description "[Molecular therapeutic approaches, for example, those directed against the fusion protein BCR-ABL with ABL-tyrosine kinase inhibitor, are on the way to creating a new avenue for the treatment of ALL.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP294057.RA8cww4AUErWn9Xu45Oy8HAeyKn1YLd1pIdZMIr1GfY_s130_provenance.
- NP294057.RA8cww4AUErWn9Xu45Oy8HAeyKn1YLd1pIdZMIr1GfY_s130_assertion evidence source_evidence_literature NP294057.RA8cww4AUErWn9Xu45Oy8HAeyKn1YLd1pIdZMIr1GfY_s130_provenance.
- NP294057.RA8cww4AUErWn9Xu45Oy8HAeyKn1YLd1pIdZMIr1GfY_s130_assertion SIO_000772 11049022 NP294057.RA8cww4AUErWn9Xu45Oy8HAeyKn1YLd1pIdZMIr1GfY_s130_provenance.
- NP294057.RA8cww4AUErWn9Xu45Oy8HAeyKn1YLd1pIdZMIr1GfY_s130_assertion wasDerivedFrom befree-20140225 NP294057.RA8cww4AUErWn9Xu45Oy8HAeyKn1YLd1pIdZMIr1GfY_s130_provenance.
- NP294057.RA8cww4AUErWn9Xu45Oy8HAeyKn1YLd1pIdZMIr1GfY_s130_assertion wasGeneratedBy ECO_0000203 NP294057.RA8cww4AUErWn9Xu45Oy8HAeyKn1YLd1pIdZMIr1GfY_s130_provenance.